Wall Street Analysts See a 69.15% Upside in Fulcrum Therapeutics (FULC): Can the Stock Really Move This High?
https://www.zacks.com/stock/news/2274184/wall-street-analysts-see-a-69-15-upside-in-fulcrum-therapeutics-fulc-can-the-stock-really-move-this-high?cid=CS-ZC-FT-tale_of_the_tape|consensus_price_target-2274184
May 15, 2024 - The consensus price target hints at a 69.2% upside potential for Fulcrum Therapeutics (FULC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
0
Wall Street Analysts See Teekay Tankers (TNK) as a Buy: Should You Invest?
https://www.zacks.com/stock/news/2274685/wall-street-analysts-see-teekay-tankers-tnk-as-a-buy-should-you-invest?cid=CS-ZC-FT-fundamental_analysis|average_broker_rating-2274685
May 16, 2024 - According to the average brokerage recommendation (ABR), one should invest in Teekay Tankers (TNK). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
0
Wall Street Analysts See Nextracker (NXT) as a Buy: Should You Invest?
https://www.zacks.com/stock/news/2274687/wall-street-analysts-see-nextracker-nxt-as-a-buy-should-you-invest?cid=CS-ZC-FT-fundamental_analysis|average_broker_rating-2274687
May 16, 2024 - The average brokerage recommendation (ABR) for Nextracker (NXT) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
0
Wall Street Analysts See Modine (MOD) as a Buy: Should You Invest?
https://www.zacks.com/stock/news/2275326/wall-street-analysts-see-modine-mod-as-a-buy-should-you-invest?cid=CS-ZC-FT-fundamental_analysis|average_broker_rating-2275326
May 17, 2024 - Based on the average brokerage recommendation (ABR), Modine (MOD) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
0
"Magnificent Seven" Stock Shake-Up -- 3 Business Stats You Need to See Right Now
https://www.fool.com/investing/2024/02/19/magnificent-7-stock-shake-up-3-business-stats-you/?source=iedfolrf0000001
Feb 19, 2024 - By one metric, Nvidia just surpassed Alphabet and Amazon in size.
0
Wall Street Analysts See Builders FirstSource (BLDR) as a Buy: Should You Invest?
https://www.zacks.com/stock/news/2227905/wall-street-analysts-see-builders-firstsource-bldr-as-a-buy-should-you-invest?cid=CS-ZC-FT-fundamental_analysis|average_broker_rating-2227905
Feb 19, 2024 - The average brokerage recommendation (ABR) for Builders FirstSource (BLDR) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
0
U.S. Stocks May See Further Downside In Early Trading
https://www.rttnews.com/story.aspx?Id=3425800
Feb 20, 2024 - After ending last Friday's trading mostly lower, stocks may see further downside in early trading on Tuesday. The major index futures are currently pointing to a lower open for the markets, with the S&P 500 futures down by 0.3 percent.
0
Sealed Air (SEE) to Report Q4 Earnings: What to Expect?
https://www.zacks.com/stock/news/2230384/sealed-air-see-to-report-q4-earnings-what-to-expect?cid=CS-ZC-FT-analyst_blog|earnings_preview-2230384
Feb 22, 2024 - Sealed Air's (SEE) Q4 results are likely to bear lower volumes, owing to recessionary pressures in the industrial and fulfillment market, and food market declines.
0
Wall Street Analysts See a 56.18% Upside in Morphic Holding, Inc. (MORF): Can the Stock Really Move This High?
https://www.zacks.com/stock/news/2231768/wall-street-analysts-see-a-56-18-upside-in-morphic-holding-inc-morf-can-the-stock-really-move-this-high?cid=CS-ZC-FT-tale_of_the_tape|consensus_price_target-2231768
Feb 26, 2024 - The average of price targets set by Wall Street analysts indicates a potential upside of 56.2% in Morphic Holding, Inc. (MORF). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
0
Wall Street Analysts See a 131.6% Upside in Relay Therapeutics, Inc. (RLAY): Can the Stock Really Move This High?
https://www.zacks.com/stock/news/2231767/wall-street-analysts-see-a-131-6-upside-in-relay-therapeutics-inc-rlay-can-the-stock-really-move-this-high?cid=CS-ZC-FT-tale_of_the_tape|consensus_price_target-2231767
Feb 26, 2024 - The mean of analysts' price targets for Relay Therapeutics, Inc. (RLAY) points to a 131.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
0